The National Institute for Health and Clinical Excellence (NICE) has published a further consultation document as part of its appraisal of bortezomib (Velcade) for the treatment of multiple myeloma.
Parasites must be correctly identified before the correct treatment is introduced. To do so, we need a fast and cheap technique that enables us to obtain the necessary results in our studies, especially in under developed countries where there are no proper infrastructures.
Normally sedentary breast cancer survivors who completed an exercise program reduced the levels of insulin in their blood, revealing a likely link between physical activity and better outcomes, researchers from Dana-Farber Cancer Institute in Boston reported at the annual meeting of the American Society of Clinical Oncology in Chicago.
Nutrition 21, Inc. (NASDAQ: NXXI) announced new published results from a 447 subject, randomized, double-blind, placebo-controlled clinical study that showed Diachrome?, a patented combination of chromium picolinate and biotin, significantly improved glycemic control in patients with poorly controlled blood sugar levels who were being treated with oral anti-diabetic medication (OADs).
The drug lapatinib shrank tumors and slowed progression of brain metastases in some patients with advanced breast cancer, according to results of a clinical trial being presented by Dana-Farber Cancer Institute scientists at the annual meeting of the American Society of Clinical Oncology.
An updated analysis of two large randomized clinical trials has found that breast cancer patients who received the monoclonal antibody trastuzumab (Herceptin) along with chemotherapy are living longer and with less risk of recurrent disease, compared to patients treated with chemotherapy alone.
The number of tumor cells circulating in the bloodstream of patients with metastatic, hormone-resistant, prostate cancer can predict how they will do with chemotherapy, according to results of an international trial.
ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) announced the presentation of data from its Quinamed? (amonafide dihydrochloride) phase 1/2a dose-escalation study, designed to identify a genotypically optimised dose of Quinamed in heavily pre-treated patients with a variety of solid tumors.
The investigational drug axitinib produced tumor regression or stable disease in almost three-out-of-four patients with advanced thyroid cancer, a research team reported June 3 at the annual meeting of the American Society for Clinical Oncology in Chicago.
A study, lead by Dr. Laura Rosi?ol, researcher of the Haematooncology Group of Hospital Cl?nic-IDIBAPS (Barcelona) in collaboration with Dr Joan Blade, researcher in the same group, administered alternately two drugs (Bortezomid and Dexamethasone) before conducting autologous bone marrow transplantations.